Outcome of Board Meeting held on Saturday, 30th May, 2026
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarey Drugs & Pharmaceuticals Ltd held its board meeting on May 30, 2026, and approved the audited standalone financial results for Q4 and FY ended March 31, 2026. For the full year, total income was Rs. 47,836.61 Lakhs (vs Rs. 48,375.57 Lakhs in FY25), showing a slight decline of about 1.1%. Profit before tax fell to Rs. 541.42 Lakhs from Rs. 610.19 Lakhs, a decline of about 11.3% YoY. However, Q4 showed strong recovery with profit of Rs. 155.74 Lakhs, nearly 3.3x the Q4 FY25 profit of Rs. 47.01 Lakhs. The auditors from Motilal & Associates LLP issued an unmodified opinion, confirming clean financials. The company also filed a statement confirming no deviation in the utilization of Rs. 797.50 Lakhs raised through convertible warrants (preferential issue), with the funds used for stated business purposes.
While full-year profit declined, the strong Q4 performance suggests recovery momentum. The unmodified audit opinion and confirmation of proper fund utilization are positive signals for investor confidence. The stock may see a neutral to slightly positive reaction given the clean audit.